AVE 2268
Alternative Names: AVE2268Latest Information Update: 02 Oct 2021
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 31 Oct 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (PO)
- 31 Oct 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in Latin America (PO)
- 31 Oct 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in South Africa (PO)